NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone”
or the “Company”) is pleased to announce significant advancements
in extracellular vesicles (EVs) functionality. Leveraging its
proprietary and patented 3D-Flow production, the Company has
achieved significantly enhanced EV functionality. These
achievements include an amplified immuno-modulatory response which
means helping the immune system to respond to injury and reducing
the inflammation activity and in parallel, significantly improved
cellular uptake, allowing NurExone’s EVs better cell penetration,
holding great promise for the Company’s future EVs-based therapies.
Through state-of-the-art production
methodologies, NurExone aims to unlock the full potential of EVs as
powerful therapeutic tools. The Company's exclusive and unique
3D-Flow process involves culturing EVs on a 3D "scaffold" and
subjecting the stem cells to flow-induced shear stress stimulation
during production (Fig. 1A). This innovative technique, which was
developed in the lab of Professor Shulamit Levenberg at the
Technion (Haifa) and exclusively licensed to the Company, has
already demonstrated increased yield in production1. The current
study, performed by the Company, assessed functional properties of
EVs, cultured using different production techniques. The EVs
derived from Human Bone Marrow Mesenchymal Stem Cells (hBM-MSC) and
produced via 3D-Flow demonstrated a superior ability to decrease
the inflammatory response of cells compared with a standard control
and other production techniques (Fig. 1B), suggesting effectiveness
in decreasing inflammation.
Furthermore, the groundbreaking 3D-Flow
production has led to EVs with significantly improved cellular
uptake, compared with EVs produced by other production techniques.
This is critical to ensure targeted delivery of therapeutic cargo
to specific cell types, maximizing the potential of EVs as drug
delivery vehicles. (Fig.1C).
EVs have gained considerable attention in recent
years due to their potential as natural therapeutic carriers.
Demonstrating modulation of immune response, and superior uptake of
EVs in the target cells will assist in moving from the laboratory
to the clinical setting. NurExone is committed to further exploring
the potency and therapeutic benefits of EVs produced through the
3D-Flow process using rigorous preclinical and clinical
studies.
The Company's wholly-owned subsidiary, NurExone
Biologic Ltd. has obtained an exclusive worldwide license from the
Technion to develop and commercialize the production process for
use for additional indications. Based on the study results, the
Company is pursuing a patent application in the United States and
other key markets under the Patent Cooperation Treaty (PCT). Once
the production process is finalized, NurExone intends to monetize
this technology by licensing it to other companies within the
global biopharmaceutical industry in addition to implementing it
within its proprietary drug platform.
Professor Shulamit Levenberg, Chief Scientific
Advisor to NurExone and Director of the Technion Center for 3D
Bioprinting expressed, “We are proud to showcase the remarkable
immune modulation and increased cellular uptake of EVs achieved
through the innovative 3D-Flow process. Together with previously
demonstrated productivity benefits, these advancements are expected
to enhance both the efficiency and the potency of EVs-based
therapies.”
Fig
1. Impact of Culturing
Conditions on Decrease in Inflammatory
Response and Uptake of EVs
Figure
1: EVs obtained from MSCs
cultured in 3D scaffolds under dynamic conditions (flow) (A)
demonstrated the most substantial decrease in the inflammatory
response of RAW 264.7 cells (B) and an increase in uptake in
neuronal cells (ReN cells) (C) compared to EVs derived cultured
under static conditions. EVs (8x107 particles) were added to RAW
264.7 cells in 96 wells for ON. LPS (200 ng/ml) was added for 6 hr.
Relative expression was assessed with qRT-PCR. HPRT was used as the
expression internal control. Relative expression was compared to
cells with either treatment or LPS alone (EVs or Anti-inflammatory
treatment - Tempol) or LPS. Tempol is an anti-inflammatory reagent
used as a positive control.
About NurExone
Biologic Inc.
NurExone Biologic Inc. is a TSX Venture
Exchange-listed pharmaceutical company that is developing a
platform for biologically-guided ExoTherapy to be delivered,
non-invasively, to patients who suffered traumatic spinal cord
injuries.
ExoTherapy, utilizing extracellular vesicles or
exosomes, was conceptually demonstrated in animal studies at the
Technion, Israel Institute of Technology. NurExone is translating
the treatment to humans, and the Company holds an exclusive
worldwide license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For further
information, please
contact:
Dr. Lior ShaltielChief Executive Officer and
Director Phone: +972-52-4803034
Inbar Paz-BenayounAdv. Head of Communications
and Investor Relations Phone: +972-52-3966695Email:
info@nurexone.com
Investor Relations (Canada) Phone: +1
905-347-5569Email: IR@nurexone.com
To download
NurExone's Earnings Presentation, please
visit:https://nurexone.com/wp-content/uploads/2023/03/Nurexone-Q4-Full-Year-Fiscal-2022-Financial-Results-March-2023.pdf
FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking
statements" that reflect the Company's current expectations and
projections about its future development. When used in this press
release, forward-looking statements can be identified by the use of
words such as "may," or by such words as "will," "intend,"
"believe," "estimate," "consider," "expect," "anticipate," and
"objective" and similar expressions or variations of such words.
Forward-looking statements are, by their nature, not guarantees of
the Company's future operational or financial performance and are
subject to risks and uncertainties and other factors that could
cause the Company's actual results, performance, prospects, or
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements. No representation or
warranty is intended with respect to anticipated future results, or
that estimates, or projections will be sustained.
Forward-looking statements are necessarily based
on estimates and assumptions made by us in light of our experience
and perception of historical trends, current conditions, and
expected future developments, as well as the factors we believe are
appropriate. Forward- looking statements in this press release
include, but are not limited to, statements relating to: our future
plans and intellectual property; our scientific and development
activities; future scientific activities and the treatment of
certain conditions; the therapeutic benefits, effectiveness, and
safety of our product candidates; and the estimated growth of the
market for acute spinal cord injuries.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
our ability to retain key personnel, our ability to continue
investing in research and development, our ability to secure
available funding and to continue as a going concern; the general
business and economic conditions of the industries and countries in
which we operate; and our ability to execute on our business
strategy.
Many risks, uncertainties, and other factors
could cause the actual results of the Company to differ materially
from the results, performance, achievements, or developments
expressed or implied by such forward-looking statements. These
risks, uncertainties, and other factors include, but are not
limited to, the following: those risk factors identified under the
heading "Risk Factors" on pages 62 to 69 of the Company's Filing
Statement dated May 12, 2022, a copy of which is available under
the Company's SEDAR profile at www.sedar.com; risks related to the
Company's early stage of development; lack of revenues to date;
government regulation; market acceptance for our products; rapid
technological change; dependence on key personnel; protection of
our intellectual property; dependence on our strategic partners;
overall economic conditions; competitive pressures; network
restrictions; and other similar factors that may cause the actual
results, performance or achievements to differ materially from
those expressed or implied in these forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of the
press release or as of the date otherwise specifically indicated
herein. Due to risks and uncertainties, events may differ
materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required pursuant to applicable securities
law. All forward-looking statements contained in the press release
are expressly qualified in their entirety by this cautionary
statement. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
_________________________________
1
https://www.newsfilecorp.com/release/141987/NurExone-Announces-Productivity-and-Quality-Pilot-Results-of-PatentPending-Process-for-3D-Scaled-Up-Exosome-Production
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c8524691-cbb0-484d-a78d-189b408fc5e9
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024